SCHEMBL5759681

SCHEMBL5759681

O=c1cc(C(F)(F)F)c2cc(Cc3ccc(S(=O)(=O)NC4CCN(Cc5ccccc5)CC4)cc3)ccc2o1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAOB P27338 3/20 0.53
HTT P42858 1/20 0.53
TP53 P04637 1/20 0.53
L3MBTL1 Q9Y468 1/20 0.53
KMT2A Q03164 4/20 0.50
ALDH1A1 P00352 2/20 0.50
SMN1; SMN2 Q16637 2/20 0.50
THRB P10828 1/20 0.50
CCR3 P51677 1/20 0.48
PDK1 Q15118 1/20 0.47
PDK2 Q15119 1/20 0.47
PDK3 Q15120 1/20 0.47
PDK4 Q16654 1/20 0.47
OPRK1 P41145 1/20 0.46
MAPT P10636 1/20 0.46
HTR1A P08908 1/20 0.45
HTR7 P34969 1/20 0.45
ADORA2B P29275 1/20 0.44
MEN1 O00255 3/20 0.44
ACHE P22303 2/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5860258 0.86 SMN1; SMN2 (0.44) HTTALDH1A1SMN1; SMN2MAPT
SCHEMBL5860196 0.85 ALDH1A1 (0.44) HTTALDH1A1SMN1; SMN2MAPT
SCHEMBL5759747 0.83 KMT2A (0.37) KMT2AALDH1A1MEN1
SCHEMBL5762386 0.83 HTT (0.53) HTTTP53L3MBTL1KMT2AALDH1A1
SCHEMBL5860408 0.79 GAA (0.46) HTTTP53L3MBTL1KMT2AALDH1A1
SCHEMBL5861426 0.79 HTT (0.47) HTTTP53L3MBTL1KMT2AALDH1A1
SCHEMBL5761750 0.78 KDM4E (0.46) KMT2AALDH1A1MEN1PKM
SCHEMBL5761768 0.78 KCNA5 (0.53) MAOBHTTKMT2AALDH1A1THRB
SCHEMBL5762790 0.78 ALDH1A1 (0.44) HTTTP53L3MBTL1KMT2AALDH1A1
SCHEMBL5761962 0.78 KDM4E (0.46) KMT2AALDH1A1MAPTMEN1PKM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7098340-B2 Quinoline/chromene derivatives as androgen antagonist WARNER LAMBERT COMPANY LLC (US) 2006-08-29 US claimed
EP-1633732-A1 BENZYL SULFONAMIDE DERIVATIVES AS ANDROGEN RECEPTOR ANTAGONISTS WARNER-LAMBERT COMPANY (US) 2006-03-15 EP claimed
US-20050137228-A1 Benzyl sulfonamide derivatives DU DANIEL Y (US) 2005-06-23 US claimed
WO-2004101544-A1 BENZYL SULFONAMIDE DERIVATIVES AS ANDROGEN RECEPTOR ANTAGONISTS WARNER-LAMBERT COMPANY LLC (US) 2004-11-25 WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050137228-A1 Benzyl sulfonamide derivatives AR, SHBG, BRDT MAOB 2029/4885HTT 2718/4885TP53 1975/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.